Results 101 to 110 of about 53,199 (230)

Protein Profile of Multiple Myeloma‐Derived Extracellular Vesicles for the Discovery of Novel Myeloma‐Related Biomarkers

open access: yesCancer Science, EarlyView.
Comparison of extracellular vesicles with parental cells through proteomic profiling, followed by an integrated bioinformatic pipeline including disease association and transcriptomic analyses, identifies candidate biomarkers for multiple myeloma. Among these, MIF emerges as a clinically relevant marker, supported by validation in patient samples and ...
Natalia Platonova   +13 more
wiley   +1 more source

Clinical trials portfolio and regulatory outcomes of ixazomib in multiple myeloma: A systematic review and meta‐analysis

open access: yes
British Journal of Haematology, EarlyView.
Veer Shah   +11 more
wiley   +1 more source

Persistent in vitro nociceptor hyperexcitability and axonal retraction produced by repeated paclitaxel doses

open access: yesThe FEBS Journal, EarlyView.
Repeated paclitaxel exposure causes long‐lasting nociceptor hyperexcitability and axonal retraction in adult sensory neurons. Using a long‐term primary nociceptor culture, we show that hyperexcitability is mediated by sequential upregulation of NaV1.8, TRPV1, TRPA1, and TRPM8 channels.
Angela Lamberti   +3 more
wiley   +1 more source

Borylcyclopropanes: Synthetic Strategies and Applications

open access: yesAngewandte Chemie, Volume 138, Issue 37, 7 September 2026.
Borylcyclopropanes (cyclopropanes bearing a boron substituent) sit at the intersection of two privileged frameworks in synthesis. This review provides the first exhaustive survey of their chemistry, spanning metal–carbene, nucleophilic cyclization, radical, hydroboration, and C─H activation routes, and documenting applications in medicinal chemistry ...
Aiza A. Butt, Joseph M. Ready
wiley   +2 more sources

The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022

open access: yes
British Journal of Haematology, EarlyView.
Claire Comerford   +25 more
wiley   +1 more source

Biogenesis of TNF‐α‐insights into proteostasis and inflammation

open access: yesThe FEBS Journal, EarlyView.
TNF‐α biogenesis, trafficking, and signalling are tightly and reciprocally coupled to cellular proteostasis systems, including ER chaperones and endoplasmic reticulum‐associated degradation. This bidirectional crosstalk determines whether TNF‐α responses are adaptive or proteotoxic.
Bailasan Haidar   +3 more
wiley   +1 more source

Bortezomib and bilateral herpes zoster

open access: yes, 2012
Bortezomib is a proteasome inhibitor that has proven to be a very effective treatment for multiple myeloma. There is considerable debate about the potential for reactivation of the varicella zoster virus (VZV) in patients with multiple myeloma during ...
DI MEO, NICOLA   +3 more
core   +1 more source

Real‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma

open access: yes
British Journal of Haematology, EarlyView.
Edvan Q. Crusoé   +20 more
wiley   +1 more source

CD36‐mediated lipid rewiring in the metabolic adaptation of tumour ecosystems

open access: yesThe FEBS Journal, EarlyView.
Nutrient deprivation drives a lipid‐centric shift in tumour metabolic symbiosis and signalling network. CD36 functions as a bidirectional bridge, transferring fatty acids from stromal donors (adipocytes, CAFs) to the ecosystem tumour‐ and microenvironment‐dependently.
Anna Sebestyén   +11 more
wiley   +1 more source

A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

open access: yes
British Journal of Haematology, EarlyView.
Runfeng Zhang   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy